LMTK2

Across TCGA pan-cancer cohorts, LMTK2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated LMTK2 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher LMTK2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LMTK2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KICH, UCS, and LIHC are the cancer types where LMTK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.079	0.891	<.001	28	view →
UCS	OS	Median	II,III,IV	0.001	0.616	<.001	24	view →
LIHC	DFS	Median	III,IV	0.045	0.361	<.001	21	view →
OV	OS	Median	II,III,IV	0.308	0.691	.033	18	view →
BRCA	DFS	Median	III,IV	0.510	0.880	<.001	10	view →
SKCM	OS	Median	II,III,IV	0.706	0.303	.029	9	view →
BLCA	DFS	Median	IV	0.201	0.484	.031	6	view →
COAD	OS	Median	All	0.577	0.873	.020	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

LMTK2–KICH (DFS)

Open the KICH breakdown →